Pharmacists performing hepatitis C antibody point-of-care screening in a community pharmacy: A pilot project

被引:37
作者
Dong, Betty J. [1 ,2 ]
Lopez, Maria [3 ]
Cocohoba, Jennifer [4 ]
机构
[1] Univ Calif San Francisco, Sch Med, Clin Pharm & Family & Community Med, Dept Clin Pharm, San Francisco, CA 94143 USA
[2] Univ Calif San Francisco, Sch Pharm, Clin Pharm & Family & Community Med, Dept Clin Pharm, San Francisco, CA 94143 USA
[3] Mission Wellness Pharm, Clin Pharm Serv, San Francisco, CA USA
[4] Univ Calif San Francisco, Sch Pharm, San Francisco, CA 94143 USA
关键词
BURDEN; COST;
D O I
10.1016/j.japh.2017.04.463
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Objectives: To describe the first community pharmacy-based hepatitis C antibody (HCV-Ab) point-of-care (POC) screening program and its outcomes in California. Setting: Community pharmacy. Practice description: Community pharmacists perform HCV-Ab POC testing, counsel patients about HCV transmission and prevention, and provide linkage to care. Practice innovation: Pharmacists implement an HCV-Ab POC screening program in collaboration with the local public health department. Evaluation: Descriptive data of the demographics of the persons receiving HCV-Ab POC screening and qualitative assessment of the attitudes and knowledge of the trained pharmacists involved in its implementation. Results: During the 3-month pilot, 6 community pharmacists performed 83 HCV-Ab rapid POC tests with 1 positive result (1.2%). Risk factors for the positive result included injection drug use, crack cocaine or methamphetamine use, and being in the high-risk birth cohort. Although some expressed reservations, pharmacists attested to the feasibility of incorporating HCV screening into their routine pharmacy work. Two major barriers identified by pharmacists for implementing HCV screening included getting non-pharmacy customers into the pharmacy for testing and balancing the time required to review test results within the normal pharmacy workflow. Conclusion: This pilot demonstrated that trained and motivated community pharmacists in partnership with the Department of Public Health could perform needed rapid HCV-Ab POC screening for potentially high-risk patients not currently in care. Community pharmacies are viable locations for screening and linkage to care owing to their easy access to knowledgeable pharmacists and accessible locations. (C) 2017 American Pharmacists Association (R). Published by Elsevier Inc. All rights reserved.
引用
收藏
页码:510 / +
页数:8
相关论文
共 17 条
[1]  
American Association for the Study of Liver Diseases, AASLD HEP C GUID
[2]   Breast Cancer-Associated Fibroblasts: Where We Are and Where We Need to Go [J].
Buchsbaum, Rachel J. ;
Oh, Sun Young .
CANCERS, 2016, 8 (02)
[3]  
Centers for Disease Control and Prevention, 2012, PARTN PHARM PREV CON
[4]   Cost-effectiveness of Early Treatment of Hepatitis C Virus Genotype 1 by Stage of Liver Fibrosis in a US Treatment-Naive Population [J].
Chahal, Harinder S. ;
Marseille, Elliot A. ;
Tice, Jeffrey A. ;
Pearson, Steve D. ;
Ollendorf, Daniel A. ;
Fox, Rena K. ;
Kahn, James G. .
JAMA INTERNAL MEDICINE, 2016, 176 (01) :65-73
[5]   Awareness of infection, knowledge of hepatitis C, and medical follow-up among individuals testing positive for hepatitis C: National Health and Nutrition Examination Survey 2001-2008 [J].
Denniston, Maxine M. ;
Klevens, R. Monina ;
McQuillan, Geraldine M. ;
Jiles, Ruth B. .
HEPATOLOGY, 2012, 55 (06) :1652-1661
[6]  
Gallup, 2015, DEPTH TOP A Z HON ET
[7]   Lost in knowledge translation: Time for a map? [J].
Graham, ID ;
Logan, J ;
Harrison, MB ;
Straus, SE ;
Tetroe, J ;
Caswell, W ;
Robinson, N .
JOURNAL OF CONTINUING EDUCATION IN THE HEALTH PROFESSIONS, 2006, 26 (01) :13-24
[8]   Point-of-care testing for infectious diseases: Opportunities, barriers, and considerations in community pharmacy [J].
Gubbins, Paul O. ;
Klepser, Michael E. ;
Dering-Anderson, Allison M. ;
Bauer, Karri A. ;
Darin, Kristin M. ;
Klepser, Stephanie ;
Matthias, Kathryn R. ;
Scarsi, Kimberly .
JOURNAL OF THE AMERICAN PHARMACISTS ASSOCIATION, 2014, 54 (02) :163-171
[9]  
Healthy People 2020, ACC HLTH SERV
[10]  
Kelling SE., 2015, INNOV PHARM, Varticle 210, DOI DOI 10.24926/IIP.V6I3.392